Go to the list of all blogs
Arthur Evans's Avatar
published in Blogs
Sep 25, 2026
Expedia Group (EXPE) Stock Drops -21.5% Amid AI Disruption Concerns

Expedia Group (EXPE) Stock Drops -21.5% Amid AI Disruption Concerns

Key Takeaways

  • EXPE declined roughly 21.5% over the past 30 days, from a close near $333.44 on August 26 to about $261.75 by September 24.
  • The selloff was driven primarily by the launch of Meta's AI assistant "Muse," which raised fears that agentic AI could bypass online travel agencies and compress take rates.
  • A Morgan Stanley downgrade to Underweight with a $235 price target added pressure, citing flat monthly active-user growth versus faster-growing rivals.
  • Strong Q2 results—adjusted EPS of $5.76 and 14% revenue growth—were largely overshadowed by structural disruption concerns.
  • The stock round-tripped over the quarter, rallying to a 52-week high near $342 in late August before giving back those gains.

Expedia Group (EXPE) Business Overview

Expedia Group, Inc. is one of the world's largest online travel platforms, connecting travelers with hotels, vacation rentals, flights, car rentals, cruises, and destination experiences. Its portfolio includes consumer brands such as Expedia.com, Hotels.com, Vrbo, Orbitz, Travelocity, and Hotwire, alongside a growing business-to-business segment that supplies travel inventory to banks, airlines, and other partners.

The company generates revenue primarily through commissions and fees on bookings, as well as advertising and B2B services. Its competitive strengths include scale, a broad loyalty ecosystem, and the Vrbo vacation-rental platform, which positions it against peers such as Airbnb (ABNB) and Booking Holdings (BKNG). Investors track EXPE closely because of its exposure to global travel demand, its growing advertising business, and its sensitivity to AI-driven shifts in how consumers search for and book travel. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

EXPE Stock Price Performance Over the Past 30 Days and Quarter

Over the trailing 30 days, EXPE fell from a closing price near $333.44 on August 26 to approximately $261.75 by September 24, a decline of roughly 21.5%. The drop accelerated in mid-to-late September, with the stock posting several single-session declines of more than 5% as AI-disruption concerns intensified across the travel sector.

The picture over the full quarter is more balanced. EXPE began July near the mid-$260s, rallied through the summer to a 52-week high around $342 in late August, and then surrendered those gains as the September repricing unfolded. Measured from early July levels to late September, the stock was essentially flat to slightly lower—down roughly 1%—despite significant intra-quarter volatility. When I reviewed the peer comparisons with Tickeron’s AI Screener, the relative underperformance stood out clearly.

What Drove the Recent 30-Day Selloff in EXPE

The primary catalyst was the launch of Meta Platforms' personal AI agent, Muse (META), on September 8. Because Muse can search, compare, and complete travel bookings directly, investors repriced the commission-based online travel agency model. The selling spread across the sector, but Expedia—with a more pure-play aggregation model—saw some of the sharpest declines, alongside Airbnb (ABNB), Booking Holdings (BKNG), and Tripadvisor (TRIP).

Separately, on September 16, Morgan Stanley downgraded EXPE to Underweight from Equal Weight with a $235 price target, citing flat monthly active-user growth in the second quarter compared with roughly 6% growth at Booking.com and about 10% at Airbnb. The firm also flagged Expedia's concentration in chain hotels, airfare, and the U.S. market as areas of greater exposure to AI-powered travel search.

Other developments weighed on sentiment. Families from Massachusetts filed a civil lawsuit in King County Superior Court against Expedia and its Vrbo entities over a deadly June vacation-rental fire in the Dominican Republic, alleging inadequate safety warnings. The company also announced a multi-year travel-insurance advertising collaboration with Redion, which carried no disclosed financial terms.

Quarterly Performance and Fundamental Strength

The broader quarterly narrative was one of strong fundamentals colliding with a structural re-rating. On August 5, Expedia reported second-quarter adjusted EPS of $5.76, beating consensus of $5.16, on revenue of $4.315 billion, up 14% year over year. Net income rose sharply, adjusted EBITDA climbed 23% to $1.119 billion, and management raised full-year revenue guidance to a range of $16.05 billion to $16.22 billion.

Beneath those results, the B2B segment remained the fastest-growing engine, with bookings rising more than 20%—well ahead of the consumer business. That strength helped push the stock to its 52-week high near $342 in late August. However, as September brought the Muse launch and the Morgan Stanley downgrade, the market shifted its focus from near-term earnings execution to the longer-term risk of disintermediation, erasing the summer's gains.

What to Watch Next for EXPE Investors

Investors should monitor Expedia's third-quarter earnings, expected in early November, for evidence of whether consumer bookings and user growth are stabilizing relative to Booking Holdings and Airbnb. The company's monthly active-user trends, full-year guidance updates, and B2B and advertising momentum will be central to the debate over whether the recent decline reflects a temporary re-rating or a structural shift.

Beyond earnings, the evolution of AI travel agents—including Meta's Muse—will remain a key variable, as will merchant acceptance of agent-driven bookings and the cost of completed transactions. Macroeconomic factors such as consumer travel demand, airfare and lodging pricing, and foreign-exchange movements also carry weight. Regulatory and legal developments, including the pending Vrbo litigation, round out the list of factors investors should follow. Checking the pattern signals via Tickeron helped confirm some of the volatility trends I was monitoring.

Exploring Tickeron AI Tools for Research

One resource I turn to regularly for identifying automated trading approaches is Tickeron’s Trending AI Robots page. It highlights a curated selection of the platform’s top-performing AI trading bots across various strategies and timeframes, helping surface options that align with current market conditions without requiring a full scan of every available robot.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: EXPE

Contributor

Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.


EXPE's Stochastic Oscillator is staying in oversold zone for 7 days

The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where EXPE's RSI Indicator exited the oversold zone, 19 of 25 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 76%.

Following a +0.82% 3-day Advance, the price is estimated to grow further. Considering data from situations where EXPE advanced for three days, in 235 of 308 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.

EXPE may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on September 23, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on EXPE as a result. In 58 of 84 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 69%.

EXPE moved below its 50-day moving average on September 08, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for EXPE crossed bearishly below the 50-day moving average on September 14, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 9 of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 64%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where EXPE declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 66%.

The Aroon Indicator for EXPE entered a downward trend on October 05, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron SMR rating for this company is 10 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 51 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 80, placing this stock slightly better than average.

The Tickeron Price Growth Rating for this company is 53 (best 1 - 100 worst), indicating steady price growth. EXPE’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Valuation Rating of 80 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (26.247) is normal, around the industry mean (24.492). P/E Ratio (16.619) is within average values for comparable stocks, (52.914). Projected Growth (PEG Ratio) (0.694) is also within normal values, averaging (1.617). Dividend Yield (0.007) settles around the average of (0.024) among similar stocks. P/S Ratio (2.315) is also within normal values, averaging (2.686).

The Tickeron PE Growth Rating for this company is 84 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

Notable companies

The most notable companies in this group are Booking Holdings Inc. (NASDAQ:BKNG), Royal Caribbean Group (NYSE:RCL), Expedia Group (NASDAQ:EXPE), Carnival Corporation Ltd. (NYSE:CCL), Trip.com Group Limited (NASDAQ:TCOM).

Industry description

Consumer sundries companies make products that usually do not have another classification, such as lawn and garden products, pest-control products, pet food and pet products like leashes, collars, and harnesses. Central Garden & Pet Company and Dogness (International) Corporation are examples of companies operating in this industry.

Market Cap

The average market capitalization across the Consumer Sundries Industry is 23.73B. The market cap for tickers in the group ranges from 4.32M to 123.13B. BKNG holds the highest valuation in this group at 123.13B. The lowest valued company is SOSAF at 4.32M.

High and low price notable news

The average weekly price growth across all stocks in the Consumer Sundries Industry was 2%. For the same Industry, the average monthly price growth was -0%, and the average quarterly price growth was 5%. LIND experienced the highest price growth at 20%, while YTRA experienced the biggest fall at -6%.

Volume

The average weekly volume growth across all stocks in the Consumer Sundries Industry was -17%. For the same stocks of the Industry, the average monthly volume growth was 56% and the average quarterly volume growth was -44%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 63
P/E Growth Rating: 66
Price Growth Rating: 57
SMR Rating: 55
Profit Risk Rating: 80
Seasonality Score: 15 (-100 ... +100)
View a ticker or compare two or three
EXPE
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a provider of on-line travel services

Industry ConsumerSundries

Industry
Other Consumer Services
Address
1111 Expedia Group Way W
Phone
+1 206 481-7200
Employees
16000
Web
https://www.expediagroup.com
Interact to see
Advertisement
UBXG stock surged +79% over the last 30 days, driven by heightened trading volume and positive market sentiment amid broader technology sector trends. Over the past quarter, the stock rose +61%, reflecting recovery from earlier lows near its 52-week bottom.
CVGI stock surged approximately +89% over the last 30 days, driven by strong Q4 2025 earnings beat on revenue and positive 2026 guidance. Over the past quarter, shares rose about +126%, reflecting improved profitability, debt reduction, and a key partnership announcement.
SAFX stock surged +104% over the past 30 days, driven by positive updates on a $10 million capital raise and merger progress. Over the past quarter, the stock rose +44%, reflecting recovery from lows amid renewable energy sector interest and strategic developments.
LONA stock surged +80% over the past 30 days, driven by positive analyst upgrades, executive appointments, and full-year financial updates highlighting pipeline progress. Over the past quarter, shares rose +48%, reflecting improved investor sentiment in biotech amid clinical advancements.
Lifetime Brands (LCUT) stock surged +77% over the last 30 days, driven by a strong Q4 earnings beat and a Zacks Rank #1 (Strong Buy) upgrade that reflects an improved earnings outlook. Over the past quarter, shares rose +48%, supported by profitability gains despite softer sales, with adjusted EBITDA reaching $50.8 million for full-year 2025.
CURV stock surged approximately +73% over the last 30 days, driven primarily by a positive reaction to Q4 and fiscal 2025 earnings that beat expectations on EPS and revenue. Over the past quarter, the stock is up around +55%, reflecting recovery from lows near $1 amid ongoing store optimization and sub-brand launches
Blaize Holdings, Inc. (BZAI) focuses on artificial intelligence (AI)-enabled edge computing solutions, offering programmable AI processors and platforms for verticals such as smart cities, defense, retail, and enterprise markets. The company's core revolves around hardware like the Graph Streaming Processor (GSP) AI accelerator, compute cards, and software tools including Blaize AI Studio—a no-code/low-code environment for deploying AI models without source code expertise. Based in El Dorado Hills, California, and founded in 2010, it went public through a merger in early 2025.
Comstock Holding Companies, Inc. (CHCI) operates as an asset manager, developer, and operator of mixed-use and transit-oriented properties, mainly in the greater Washington, D.C. metropolitan area. The company targets high-growth urban and suburban markets, overseeing a portfolio that spans residential, commercial, hospitality, and parking assets near key metro stations. Its asset-light, fee-based model delivers recurring revenue through property management, leasing, development services, and asset recapitalization for institutional investors, family offices, and governments.
GE Aerospace (GE) stock declined -12% over the past 30 days, falling from around $333 to $293, amid profit-taking after record highs near $348. Over the past quarter, the stock is down -8%, reflecting post-earnings selloff despite strong Q4 2025 results with 20% revenue growth.
ARM stock surged +26% over the past 30 days, driven by announcements of in-house chip production and strong analyst upgrades amid AI enthusiasm. Over the past quarter, the stock climbed +38%, reflecting robust Q3 earnings beat with 26% revenue growth and data center royalty doubling.
Sable Offshore Corp. (SOC) is an independent oil and gas company focused on offshore operations in federal waters off California. The company owns and operates three platforms in the Santa Ynez Unit (SYU), spanning 16 federal leases across approximately 76,000 acres, along with subsea pipelines for crude oil, natural gas, and produced water transport to onshore facilities. Its core business model centers on restarting and developing prolific fields like the SYU, which had been idle due to regulatory and legal hurdles following a 2015 pipeline spill.
NBR stock rose approximately +12% over the last 30 days, driven by positive momentum in the oil and gas drilling sector and strong Q4 earnings beat. Over the past quarter, the stock surged +58%, fueled by robust YTD performance, debt reduction efforts, and improved operational results in international drilling.
Patterson-UTI Energy, Inc. (PTEN) stands out as a leading provider of drilling and completion services to oil and natural gas exploration and production companies, primarily in the United States and select international markets. The company operates through three main segments: Drilling Services, which includes contract drilling rigs and directional drilling; Completion Services, encompassing hydraulic fracturing, wireline, and pumping; and Drilling Products, offering specialized drill bits globally, including in the Middle East.
As a provider of onshore drilling and completion services, Patterson-UTI Energy (PTEN) is gearing up for a key Q1 2026 earnings report against the backdrop of fluctuating oil prices and steady U.S. rig demand. The company's integrated approach across Drilling Services, Completion Services, and Drilling Products gives it a solid footing in North American shale plays. In my view, recent quarters like Q4 2025, where revenue exceeded estimates despite a net loss, highlight its resilience. This upcoming report will offer insights into activity levels, margin trends, and capital discipline amid supply growth and geopolitical tensions. With strong free cash flow and recent dividend increases, PTEN's focus on shareholders stands out, making this a critical gauge for the 2026 outlook in the cyclical oilfield services sector.
When geopolitical turmoil sends markets into chaos, most retail traders freeze — but Tickeron's Energy (OXY, EOG, DVN, FANG, APA, MTDR) AI Trading Agent is built to thrive in exactly these conditions. This 15-minute and 60-minute AI-powered robot has delivered a +76.22% annualized return with a 64.21% win rate and a Profit Factor of 2.70 — trading six of the most volatile and opportunity-rich energy tickers on the market.
The global energy sector is on fire — literally and figuratively. With crude oil prices swinging 20–30% in response to geopolitical flashpoints, OPEC+ production cuts, and escalating conflicts in Eastern Europe and the Middle East, traders who aren't using AI-powered tools are flying blind. Enter Tickeron's Energy (Oil & Gas – E&P) AI Trading Agent — a 60-minute signal robot built exclusively around five high-impact Exploration & Production tickers, now posting a staggering +49% Annualized Return and +1,251% 30-Day Annualized Return, with $14,703 in closed-trade P&L on a $30,000 simulated balance.
From what I see, Cheniere Energy Partners (CQP) holds a commanding position through its ownership and operation of the Sabine Pass LNG terminal in Louisiana, the largest LNG production facility in the U.S. with approximately 30 million tonnes per annum (mtpa) capacity across six trains, alongside the connected Creole Trail Pipeline. This setup makes CQP a leader in U.S. LNG exports, which have accounted for about 11% of global supply in recent years. The company's ~80% contracted production through long-term sale and purchase agreements (SPAs) provides revenue stability, with weighted average remaining lives of around 13 years.
In my view, Regeneron Pharmaceuticals holds a strong leadership position in biotechnology, thanks to its proprietary VelociSuite technologies, including VelocImmune for fully human antibody discovery. This enables a robust pipeline across immunology, oncology, ophthalmology, and rare diseases. The company's integrated model—from discovery to commercialization—drives high R&D productivity, with approximately 45 clinical programs and key partnerships like Sanofi for Dupixent and Bayer for EYLEA.
As I review argenx SE's place in the market, its strong footing in immunology stands out. This commercial-stage biopharmaceutical company focuses on differentiated antibody therapies for severe autoimmune diseases. The flagship product, VYVGART (efgartigimod), a first-in-class neonatal Fc receptor (FcRn) inhibitor, has secured leadership in generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP), with approvals across the U.S., Europe, and Japan. The Immunology Innovation Program (IIP) fuels a robust pipeline, featuring next-generation FcRn candidates like ARGX-213 and ARGX-124, alongside first-in-class assets such as empasiprubart (C2 inhibitor, ARGX-117) and adimanebart (MuSK agonist).
I've long admired Alnylam Pharmaceuticals as the pioneer in RNA interference (RNAi) therapeutics, a gene-silencing technology that has delivered six approved products, including AMVUTTRA (vutrisiran), ONPATTRO (patisiran), GIVLAARI (givosiran), and OXLUMO (lumasiran). The company's proprietary platform, enhanced by GalNAc conjugation for liver targeting and emerging extra-hepatic delivery innovations, creates a solid competitive moat in precision genetic medicines.